This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While the Genetic Information Nondiscrimination Act (GINA) prohibits discrimination by healthinsurancecompanies and employers based on a genetic test result, GINA does not apply to life, long-term care, or disability insurance. Once a sample is received at Invitae for a panel test, what happens next?
To recap: Part 1 of the series focused on providers This part, Part 2, focuses on payers (insurancecompanies) Part 3 (by Marlana Voerster ) will focus on medical-device organizations First off: the bad news in trust for payers Gallup’s polling data among U.S.
When taken on its own, the polypill reduced by about 20% the risk of heart attack, stroke, procedures to reopen clogged arteries and other heart disease, the researchers reported. The polypill combined with daily low-dose aspirin was even more effective, reducing heart health problems by up to 40%, the findings showed. About 4.1%
Whatever the court finally decides is likely to have enormous ramifications, said Dr. Renuka Tipirneni, a health policy researcher and member of the University of Michigan’s Institute for Healthcare Policy and Innovation.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content